The updated Medscheme specialised drug list for 2023 has been published
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Impact of Practice-Level Telehealth on Quality Outcomes in Chronic Care
Practice-level telehealth quality outcomes remained stable for access and preventable hospitalizations among Medicare beneficiaries with chronic conditions during the COVID-19 pandemic. High-adopting primary care practices preserved care continuity while delivering modestly lower performance on s...
Large Language Models in Evidence-Based Medicine
Large language models deliver rapid synthesis of medical literature, but according to research on fast information and slow evidence, they cannot independently generate validated evidence for clinical decisions. These tools sit at a...
African Pharmacogenomic Integration Enhancing Essential Medicine Prescribing in Africa
African Pharmacogenomic Integration has become an urgent policy priority, with evidence showing that more than 10 percent of essential medicines across Africa require genetically guided prescribing to prevent harm and improve outcomes in diverse populations. Current dosage guidelines for HIV, ...